Catégorie : Cannabidiol

Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression, Clarissa Laczkovics et al., 2020

Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Case Report Clarissa Laczkovics · Oswald D. Kothgassner · Anna Felnhofer · Claudia M. Klier Neuropsychiatrie, 2020, 4 p. Doi : 10.1007/s40211-020-00334-0 Summary In this report, we present a case of a 16,9- year-old patient with multiple substance use disorder (cannabis, MDMA, cocaine, ecstacy), severe depression, social phobia and narcissistic personality disorder. We administered Cannabidiol (CBD) capsules in different dosages (starting dosage 100 mg up to 600 mg over 8 weeks) after unsuccessful treatment with antidepressants. CBD was a safe and well tolerated medication for this patient. Upon treatment with CBD and [...]

Lire la suite

Species-specific susceptibility to cannabis-induced convulsions, Benjamin J Whalley et al., 2018

Species-specific susceptibility to cannabis-induced convulsions Benjamin J Whalley, Hong Lin, Lynne Bell, Thomas Hill, Amesha Patel, Roy A Gray, C Elizabeth Roberts, Orrin Devinsky, Michael Bazelot, Claire M Williams and Gary J Stephens British Journal of Pharmacology, 2018, 1-18. Doi : 10.1111/bph.14165   BACKGROUND AND PURPOSE Numerous claims are made for cannabis’ therapeutic utility upon human seizures, but concerns persist about risks. A potential confounder is the presence of both Δ9-tetrahydrocannabinol (THC), variously reported to be pro- and anticonvulsant, and cannabidiol (CBD), widely confirmed as anticonvulsant. Therefore, we investigated effects of prolonged exposure to different THC/CBD cannabis extracts on seizure activity and associated measures of endocannabinoid [...]

Lire la suite

IACM-Bulletin du 14 Février 2020

IACM-Bulletin du 14 Février 2020 Science/Animal: Le cannabigerol est efficace contre les infections par des bactéries résistantes aux antibiotiques Economy/Écologie: Données sur la quantité d'électricité consommée par l'industrie du cannabis Science/Homme: Environ la moitié des patients souffrant de lombalgie ont pu arrêter toute consommation d'opioïdes après avoir commencé la consommation de cannabis Europe/ONU: La Commission Européenne propose un vote unifié de l'UE sur la programmation de l’OMS sur le cannabis Science/Homme: De nombreux patients atteints d'arthrite consomment du cannabis Science/Homme: Le cannabis peut être utile contre l'insomnie chez les personnes âgées souffrant de douleur [...]

Lire la suite

The therapeutic role of Cannabidiol in mental health : a systematic review, Khan R. at al., 2020

The therapeutic role of Cannabidiol in mental health : a systematic review Rabia Khan, Sadiq Naveed, Nadeem Mian, Ania Fida, Muhammad Abdur Raafey and Kapil Kiran Aedma Journal of Cannabis Research, 2020, 2, 2 doi : 10.1186/s42238-019-0012-y   Abstract Background : The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use. Objective : To summarize the clinical outcomes, study designs and limitations for the use of CBD and nabiximols (whole plant extract from Cannabis sativa L. that has been purified into 1:1 ratio of CBD and delta-9- tetrahydrocannabinol) in the treatment of psychiatric disorders. Materials and method : A systematic review was [...]

Lire la suite

Le cannabidiol, un agent thérapeutique prometteur ?, Benjamin Rolland et al., 2019

Le cannabidiol, un agent thérapeutique prometteur ? Benjamin Rolland , Mathieu Chappuy, Patrizia Carrieri SWAPS, 3e et 4e trimestre 2019, n° 92-93, , 5-6.   Deuxième cannabinoïde le plus étudié après le THC, sans effet psychoactif, le cannabidiol dispose de propriétés thérapeutiques intéressantes, notamment en psychiatrie. Le point sur les recherches La grande famille des cannabinoïdes Les cannabinoïdes sont un ensemble de substances capables d’activer les récepteurs du même nom (« récepteurs cannabinoïdes »). Il existe deux grandes familles de récepteurs cannabinoïdes, CB1 et CB2. Dans le système nerveux central, c’est surtout CB1 qui est exprimé, alors que CB2 est principalement présent dans le système immunitaire. [...]

Lire la suite

THCp – Newly discovered and highly potent phytocannabinoid, cannabislifenetwork.com, 2020

THCp – Newly discovered and highly potent phytocannabinoid Source : cannabislifenetwork.com Publié le 1 Fév 2020 We have discovered so much about cannabis over the years, but it’s vast, intricate, pharmacological map is missing many major regions. CBD dominant varieties have exploded in demand, yet the cannabinoid is still only partially understood, and there is still CBG and CBN just around the market’s corner. Now, brand new forms of THC and CBD, THCp and CBDp, respectively, have been discovered; evidence that the map’s expanse is still beyond our grasp. Phytocannabinoids over synthetics Lately, stories of newly discovered cannabinoids are strewn with the accomplishments of a biochemist [...]

Lire la suite

Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review, Jerome Sarris et al., 2020

Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review Jerome Sarris, Justin Sinclair, Diana Karamacoska, Maggie Davidson and Joseph Firth BMC Psychiatry, 2020, 20, 24, 1-14. Doi : 10.1186/s12888-019-2409-8   Abstract Background : Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known. Methods : The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted. Current evidence regarding [...]

Lire la suite

Que (Devrait-on) Savoir sur la Pharmacologie du Cannabidiol ?, Addictovigilance, 2020

Que (Devrait-on) Savoir sur la Pharmacologie du Cannabidiol ? Article rédigé par les Centres d’Addictovigilance de Grenoble, Marseille, Paris Addictovigilance, Bulletin de l’Association des Centres d’Addictovigilance, 2020, 13. www.addictovigilance.fr Messages clefs Les phyto-cannabinoïdes et les cannabinoïdes de synthèse ont des effets très variés,utiles à caractériser d’un point devue pharmacologique pour mieux préciser les effets de chacun et leurs éventuelles interactions chez l’Homme, a fortiori dans un contexte de large diffusion. Le cannabidiol (CBD) est l’un des principaux phyto-cannabinoïdes présent dans Cannabis sativa, avec le tétrahydrocannabinol (THC). Le CBD a une action pléiotropique notamment sur les récepteurs à la sérotonine, à la dopamine et pas ou très peu [...]

Lire la suite

Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice, Eva M. Schleicher et al., 2019

Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice Eva M. Schleicher, Frederik W. Ott, Melanie Müller, Barbara Silcher, Marius E. Sichler, Maximilian J. Löw, Jannek M. Wagner and Yvonne Bouter Frontiers in Behavioral Neuroscience, 2019, Volume 13, Article 94 doi : 10.3389/fnbeh.2019.00094   The Cannabis plant contains more than 100 currently known phytocannabinoids. Regarding the rising consumption of the non-psychotropic phytocannabinoid cannabidiol (CBD) in people’s everyday life (e.g., beauty products, food and beverages), the importance of studies on the influence of CBD on healthy humans and rodents is evident. Therefore, the behavioral profile of CBD was investigated with [...]

Lire la suite

As CBD Oil Flirts with Mainstream, Questions Mount, Kathleen Doheny, Medscape, 2018

As CBD Oil Flirts with Mainstream, Questions Mount Kathleen Doheny Medscape, June 11, 2018 Anxiety is a given for Jessica Singer, 25, who juggles her job at a marijuana dispensary with her night-time gigs as a stand-up comedian in Los Angeles. So when it’s time for bed, "I can't turn off my brain,'' she says. Now she does, with the help of a new bedtime ritual -- a ''snack" of two gummy bears containing CBD. CBD, or cannabidiol, is a substance from marijuana that lacks the ''high'' of the THC (tetrahydro-cannabinol) also found in marijuana. The remedy is affordable for her -- about $35 [...]

Lire la suite